of 100.327%, equivalent to an issue-spread of 3 month NIBOR + 1.18% p.a. Entra is a leading owner, manager, and developer of office properties in Norway. The company owns and manages around 80 ...
Euronext would like to inform clients that the following new indices will be calculated and disseminated on Set of Channels 13 ‘Euronext Indices’ of MDG as from 21 October 2025. We have updated our ...
appreciate you registering your attendance with [email protected]. "2025 is a transformational year for Xplora, with Doro opening a large new market opportunity in the Senior market and with our ...
16 October 2025 Kistefos AS (“Kistefos”) has today successfully completed a NOK 200 million tap issue of its outstanding senior unsecured bond with maturity in March 2030 and with ticker “KIST12 PRO” ...
(1) Pursuant to Article 223-11 of the Règlement général de l’Autorité des marchés financiers, number calculated on the basis of all shares to which voting rights are attached, including shares for ...
Please see attachment on www.newsweb.no More information:Access the news on Oslo Bors NewsWeb site ...
negative USD 39 million from our open cargo contracts and hedging transactions, we ended the quarter with a gross trading result of approximately minus USD 24 million. After general and administrative ...
AF Gruppen (AFG) har inngått kontrakt med Statkraft for rehabilitering av Hyttfossdammen i Trondheim kommune. Rehabiliteringen av dammen sk ...
Home Equities - Stocks - Shares Company Press Releases BE Semiconductor Industries N.V. Announces 2025 Third Quarter Conference Call and Webcast Details ...
28 October 2025. Today, the company provides preliminary operational figures. Net production attributable to BW Energy was 2.4 million barrels of oil (mmbbls) in the third quarter 2025, equivalent to ...
roro carriers was increased from USD 14 per net ton to USD 46 per net ton. Fees will be payable as of October 14, 2025. Based on the substantial increase in fees compared to the previous update of ...
13:00 CEST Press Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback